Overexpression of Growth-Related Oncogene-β Is Associated with Tumorigenesis, Metastasis, and Poor Prognosis in Ovarian Cancer

Table 1

Relationship between the expression of GRO-β and clinicopathological characteristics in ovarian cancer.

Characteristic		Low or no expression	High expression	Pearson	value
Total	136	61	75
Age				2.051	0.152
≤60	94	46 (48.94)	48 (51.06)
>60	42	15 (35.71)	27 (64.29)
Histological type				1.176	0.555
Serous	89	37 (41.57)	52 (58.43)
Endometrioid	13	7 (53.85)	6 (46.15)
Others	34	17 (50.00)	17 (50.00)
Differentiation				1.083	0.298
Low	28	15 (53.57)	13 (46.43)
High	108	46 (42.59)	62 (57.41)
FIGO stage				4.593
I~II	80	42 (52.50)	38 (47.50)
III~IV	56	19 (33.93)	37 (66.07)
CEA level				1.636	0.201
≤5	80	34 (42.50)	46 (57.50)
>5	13	8 (61.54)	5 (38.46)
Unknown	43	19	24
CA19-9 level				0.053	0.817
≤37	70	32 (45.71)	38 (54.29)
>37	21	9 (42.86)	12 (57.14)
Unknown	45	20	25
CA125 level				0.853	0.355
≤35	12	4 (33.33)	8 (66.67)
>35	82	39 (47.56)	43 (52.44)
Unknown	42	18	24
CA153 level				1.457	0.227
≤31	38	20 (52.63)	18 (47.37)
>31	48	19 (39.58)	29 (60.42)
Unknown	50	22	28
SF level				2.686	0.101
≤204	59	30 (50.85)	29 (49.15)
>204	28	9 (32.14)	19 (67.86)
Unknown	49	22	27
Ascites				4.916
No	48	26 (54.17)	22 (45.83)
Yes	42	13 (30.95)	29 (69.05)
Unknown	46	22	24
Lymph node and other metastases				26.097	<
No	60	37 (61.67)	23 (38.33)
Yes	76	24 (31.58)	52 (68.42)

.
Others: clear cell, nine cases; mucinous, seven cases; transitional cell, six cases; mixed, 12 cases.